Ocular Therapeutix Loses Sight Of Commercial Prospects
This article was originally published in Scrip
You may also be interested in...
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.